Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anastozole (Arimidex)
Anastozole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Arimidex 1mg + Nolvadex placebo |
| 2 | ACTIVE_COMPARATOR | Arimidex placebo + Nolvadex 20mg |
| 3 | ACTIVE_COMPARATOR | Arimidex 1mg + Nolvadex 20mg |
| Name | Type | Description |
|---|---|---|
| Anastozole (Arimidex) | DRUG | 1mg, orally, once daily |
| Tamoxifen (Nolvadex) | DRUG | 20mg, orally, once daily |
| Anastozole (Arimidex) placebo | DRUG | 1mg, orally, once daily |
| Tamoxifen (Nolvadex) placebo | DRUG | 20mg, orally, once daily |
Inclusion Criteria: * Patients with histologically proven operable invasive breast cancer * Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy * Women defined as post-menopausal Exclusion Criteria: * Patients in who...
Top 20 of 87 competitors
Anastozole is used for the treatment of breast cancer. It is a small molecule therapy studied in a Phase 3 clinical program in this indication. The pivotal trial enrolled postmenopausal women aged 45 years and older with breast cancer.
Anastozole is developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the Phase 3 ATAC trial evaluating the drug in breast cancer.
Anastozole is in Phase 3 development for breast cancer. The Phase 3 ATAC trial, NCT00849030, has been completed. Anastozole is an investigational agent in this program rather than a newly approved product.
Anastozole was evaluated in the Phase 3 ATAC trial, registered as NCT00849030, titled Arimidex, Tamoxifen Alone or in Combination. The trial enrolled 9,358 female participants aged 45 years and older with breast cancer and is now completed.
The ATAC trial was a Phase 3, randomized, double-blind study with an active control comparator. It enrolled 9,358 female breast cancer patients aged 45 years and older and did not use biomarker selection for enrollment. The trial is listed as completed.
Anastozole is also known as Arimidex. The name Arimidex appears in the title of the Phase 3 ATAC trial, which stands for Arimidex, Tamoxifen Alone or in Combination. Both names refer to the same AstraZeneca small molecule developed for breast cancer.